Cell Therapy Firm Kyverna Eyes $200M IPO As Pipeline Builds

By Tom Zanki · February 1, 2024, 4:37 PM EST

Autoimmune diseases-focused drug developer Kyverna Therapeutics Inc. on Thursday unveiled a price range for an estimated $200 million initial public offering, guided by Paul Hastings LLP and underwriters counsel Covington &...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Healthcare Authority Deals & Corporate Governance

Already have access? Click here to login

Get instant access to the one-stop news source for business lawyers

Sign up now for free access to this content

Email (NOTE: Free email domains not supported)

First Name

Last Name

Phone Number (###-###-####)

PLEASE NOTE: A verification email will be sent to your address before you can access your trial.

Password (at least 8 characters required)

Confirm Password

Job Title

Select at least one primary interest:

Healthcare Authority

Law360 Healthcare Authority may contact you in your professional capacity with information about our other products, services and events that we believe may be of interest.

You’ll be able to update your communication preferences via the unsubscribe link provided within our communications.

We take your privacy seriously. Please see our Privacy Policy.

Start Reading

Already have access?

Email:
Password: Forgot your password?
Remember login
Sign In

Sign up for our Healthcare Authority Deals & Corporate Governance newsletter

You must correct or enter the following before you can sign up:

Please provide a professional email:

Healthcare Authority

Law360 Healthcare Authority takes your privacy seriously. Please see our Privacy Policy.